1A9bnbK

●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
● ●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
● ●
●
●
●
●
●
● ●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
● ●
●
●
● ●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
● ●
●
●
●
●
●
●
●
●
● ●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
● ●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
128 THIRD WHO REPORT ON NEGLECTED TROPICAL DISEASES
***
Investment targets for active case-finding and treatment and care of leprosy (including medicines),
per capita, 2015–2030
2015 2020
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
● ●
●
●
2025 2030
US per capita
● 0.1
● 0.2
● 0.3
● 0.4
0.5
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
Notes: These targets do not replace any existing country plans or budgets. The investment target is divided by total population within a given country. All
numbers expressed in US$ are constant (real) US$, adjusted to reflect purchasing power in the United States of America in 2015.
elimination programmes focusses primarily on the cost-effectiveness of interventions to
detect and treat more cases earlier. 4,5 The challenge is to deliver those treatments early
enough to prevent further transmission.
This report targets an investment of about US$ 37 million (US$ 32–42 million) on average
each year during 2015–2030 for contact tracing, treatment and care. Investment targets
decrease slowly over time, from US$ 52 million (US$ 45–58 million) in 2015 to US$ 30
million (US$ 25–34 million) by 2030. Of the total, only about 7% is accounted for by the
market value of donated medicines. About 13% may be required for contact tracing. Most
of the investment required (about 80%) is for general health services, including surgery and
rehabilitation.
_____________________
1
Abedi H, Javadi A, Naji S. An exploration of health, family and economic experiences of leprosy patients, Iran. Pak J Biol
Sci PJBS. 2013;16:927–32.
2
Entezarmahdi R, Majdzadeh R, Rahimi Foroushani A, Nasehi M, Lameei A, Naieni KH. Inequality of leprosy disability
in Iran, clinical or socio-economic inequality: an extended concentration index decomposition approach. Int J Prev Med.
2014;5:414–23.
3
Cabral-Miranda W, Chiaravalloti Neto F, Barrozo LV. Socio-economic and environmental effects influencing the
development of leprosy in Bahia, north-eastern Brazil. Trop Med Int Health. 2014;19:1504–14. doi:10.1111/tmi.12389.
4
Idema WJ, Majer IM, Pahan D, Oskam L, Polinder S, Richardus JH. Cost-effectiveness of a chemoprophylactic
intervention with single dose rifampicin in contacts of new leprosy patients. PLoS Negl Trop Dis. 2010;4:e874.
doi:10.1371/journal.pntd.0000874.
5
Ezenduka C, Post E, John S, Suraj A, Namadi A, Onwujekwe O. Cost-effectiveness analysis of three leprosy case detection
methods in Northern Nigeria. PLoS Negl Trop Dis. 2012;6:e1818. doi:10.1371/journal.pntd.0001818.